Safety and tolerability of intravitreal umedaptanib pegol (anti-FGF2) for neovascular age-related macular degeneration (nAMD): a phase 1, open-label study

Overview of attention for article published in Eye, December 2023

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (96th percentile)
High Attention Score compared to outputs of the same age and source (99th percentile)

So far, Altmetric has seen 6 news stories from 6 outlets.

– Intravitreal umedaptanib pegol (an investigational anti-FGF2 aptamer) is safe, well tolerated, and effective in treatment naïve…

RIBOMIC Inc., a clinical stage pharmaceutical company specializing in aptamer therapeutics (TOKYO:4591), today announced that…

- Intravitreal umedaptanib pegol (an investigational anti-FGF2 aptamer) is safe, well tolerated, and effective in treatment naïve…

- Intravitreal umedaptanib pegol (an investigational anti-FGF2 aptamer) is safe, well tolerated, and effective in treatment naïve…

This page shows the most recent news stories that mention this research output.

Click here to find out how to access more activity, including 2 additional news stories.